Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Fig. 2

American College of Rheumatology (ACR) response rates over time in the per-protocol population, with nonresponder imputation approach. To estimate the difference in proportions between the two treatment groups, we used the exact binomial test. ACR20, ACR50 and ACR70 denote the ACR 20 %, 50 % and 70 % improvement criteria, respectively. CI confidence interval, RP reference product (i.e., reference infliximab)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us